Last reviewed · How we verify
NPC-12Y gel
NPC-12Y gel is a Small molecule drug developed by Nobelpharma. It is currently in Phase 3 development for Wound healing and tissue regeneration (specific indication under investigation in Phase 3).
NPC-12Y is a topical gel formulation designed to promote wound healing and tissue regeneration through growth factor delivery.
NPC-12Y is a topical gel formulation designed to promote wound healing and tissue regeneration through growth factor delivery. Used for Wound healing and tissue regeneration (specific indication under investigation in Phase 3).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | NPC-12Y gel |
|---|---|
| Sponsor | Nobelpharma |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Wound Care |
| Phase | Phase 3 |
Mechanism of action
NPC-12Y gel is a regenerative medicine product that appears to work by delivering bioactive compounds to enhance wound healing processes. The exact molecular mechanism is proprietary to Nobelpharma, but topical gels in this class typically promote angiogenesis, collagen deposition, and epithelialization at the wound site.
Approved indications
- Wound healing and tissue regeneration (specific indication under investigation in Phase 3)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPC-12Y gel CI brief — competitive landscape report
- NPC-12Y gel updates RSS · CI watch RSS
- Nobelpharma portfolio CI
Frequently asked questions about NPC-12Y gel
What is NPC-12Y gel?
How does NPC-12Y gel work?
What is NPC-12Y gel used for?
Who makes NPC-12Y gel?
What development phase is NPC-12Y gel in?
Related
- Manufacturer: Nobelpharma — full pipeline
- Therapeutic area: All drugs in Dermatology/Wound Care
- Indication: Drugs for Wound healing and tissue regeneration (specific indication under investigation in Phase 3)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing